Hepatitis B Virus Reactivation Potentiated by Biologics

被引：23
作者：
Ogawa, Eiichi [1 ]
Wei, Mike T. [2 ]
Nguyen, Mindie H. [2 ]
机构：
[1] Kyushu Univ Hosp, Dept Gen Internal Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan
[2] Stanford Univ, Med Ctr, Dept Med, Div Gastroenterol & Hepatol, 750 Welch Rd,Suite 210, Palo Alto, CA 94304 USA
来源：
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA | 2020年 / 34卷 / 02期
关键词：
Hepatitis B virus; Reactivation; Prophylaxis; Nucleos(t)ide analogue; CHEMOTHERAPY-INDUCED REACTIVATION; HBV REACTIVATION; C VIRUS; HEPATOCELLULAR-CARCINOMA; LAMIVUDINE THERAPY; ANTIVIRAL THERAPY; TARGETING BTK; T-CELLS; INFECTION; PATHOGENESIS;
D O I：
10.1016/j.idc.2020.02.009
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Hepatitis B virus (HBV) reactivation can be a serious complication for patients with chronic or resolved HBV infection when treated with biologics. For HBsAg-positive patients receiving biologics, the risk of HBV reactivation is moderate to high. HBsAg-negative/anti-HBc positive patients are at lower risk of HBV reactivation than HBsAg-positive patients. However, patients taking anti-CD20 agents, such as rituximab, have high risk of HBV reactivation (>10%), so antiviral prophylactic therapies are required. This review provides the different classes of biologics associated with HBV reactivation, stratifies the various reactivation risk levels by HBV status and biologic agent, and discusses management strategies.
引用
收藏
页码：341 / +
页数：20
相关论文
共 87 条
  • [21] Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports
    Evens, A. M.
    Jovanovic, B. D.
    Su, Y. -C.
    Raisch, D. W.
    Ganger, D.
    Belknap, S. M.
    Dai, M. -S.
    Chiu, B. -C. C.
    Fintel, B.
    Cheng, Y.
    Chuang, S. -S.
    Lee, M. -Y.
    Chen, T. -Y.
    Lin, S. -F.
    Kuo, C. -Y.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (05) : 1170 - 1180
  • [22] Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
    Ferrara, N
    Hillan, KJ
    Gerber, HP
    Novotny, W
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) : 391 - 400
  • [23] Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo
    Ferrari, Silvia Martina
    Bocci, Guido
    Di Desidero, Teresa
    Elia, Giusy
    Ruffilli, Ilaria
    Ragusa, Francesca
    Orlandi, Paola
    Paparo, Sabrina Rosaria
    Patrizio, Armando
    Piaggi, Simona
    La Motta, Concettina
    Ulisse, Salvatore
    Baldini, Enke
    Materazzi, Gabriele
    Miccoli, Paolo
    Antonelli, Alessandro
    Fallahi, Poupak
    [J]. ONCOLOGY REPORTS, 2018, 39 (05) : 2225 - 2234
  • [24] Combined Blockade of Programmed Death-1 and Activation of CD137 Increase Responses of Human Liver T Cells Against HBV, But Not HCV
    Fisicaro, Paola
    Valdatta, Caterina
    Massari, Marco
    Loggi, Elisabetta
    Ravanetti, Lara
    Urbani, Simona
    Giuberti, Tiziana
    Cavalli, Albertina
    Vandelli, Carmen
    Andreone, Pietro
    Missale, Gabriele
    Ferrari, Carlo
    [J]. GASTROENTEROLOGY, 2012, 143 (06) : 1576 - +
  • [25] PERSISTENCE OF HEPATITIS-B VIRUS-DNA IN THE LIVER AFTER LOSS OF HBSAG IN CHRONIC HEPATITIS-B
    FONG, TL
    DIBISCEGLIE, AM
    GERBER, MA
    WAGGONER, JG
    HOOFNAGLE, JH
    [J]. HEPATOLOGY, 1993, 18 (06) : 1313 - 1318
  • [26] Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation
    Frazer-Abel, A.
    Sepiashvili, L.
    Mbughuni, M. M.
    Willrich, M. A. V.
    [J]. ADVANCES IN CLINICAL CHEMISTRY, VOL 77, 2016, 77 : 1 - 75
  • [27] Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study
    Gane, Edward
    Verdon, Daniel J.
    Brooks, Anna E.
    Gaggar, Anuj
    Anh Hoa Nguyen
    Subramanian, G. Mani
    Schwabe, Christian
    Rod Dunbar, P.
    [J]. JOURNAL OF HEPATOLOGY, 2019, 71 (05) : 900 - 907
  • [28] Mechanisms of disease: Hepatitis B virus infection - Natural history and clinical consequences
    Ganem, D
    Prince, AM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) : 1118 - 1129
  • [29] Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?
    Giammarco, Sabrina
    de latour, Regis Peffault
    Sica, Simona
    Dufour, Carlo
    Socie, Gerard
    Passweg, Jakob
    Kroger, Nicolaus
    Petersen, Eefke
    Van Lint, Maria Teresa
    Oneto, Rosi
    Signori, Alessio
    Bacigalupo, Andrea
    [J]. BLOOD, 2018, 131 (17) : 1989 - 1992
  • [30] Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment
    Gill, Harinder
    Leung, Garret M. K.
    Seto, Wai-Kay
    Kwong, Yok-Lam
    [J]. ANNALS OF HEMATOLOGY, 2019, 98 (01) : 215 - 218
123456789